The last decade has witnessed an intensive scientific debate triggered by the fact that the majority of subjects with probable or definite FH based on clinical and biochemical criteria cannot be confirmed genetically (e.g., do not have any detectable variation in LDL-R, APOB, and PCSK9). Here, PCSK9 is linked to familial hyperaldosteronism.